This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Richard Bergenstal
University of Minnesota, Minneapolis, USA

Richard M. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center, HealthPartners Institute, St. Louis Park, MN, USA. He is Clinical Professor in the Department of Medicine at the University of Minnesota, Minneapolis–Saint Paul, MN, USA, and served as President, Science & Medicine of the American Diabetes Association (ADA) in 2010. In 2007, Dr Bergenstal was named the ADA’s Outstanding Physician Clinician of the Year, and in 2010 he was awarded the Banting Medal for Service for outstanding leadership and service to the ADA. He received his MD and endocrine training from the University of Chicago, Chicago, IL, USA, where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983.


Dr Bergenstal’s clinical research has focused on glucose control and diabetes complications and advanced technology, including continuous glucose monitoring (CGM) and automated insulin delivery systems. He has served as a Principal Investigator (PI) of several National Institutes of Health (NIH) trials (DCCT, ACCORD, GRADE) and two technology-focused NIH grants, an insulin dose advisor system and a study of next-generation automated insulin delivery systems, and a Co-PI on a Patient-Centered Outcomes Research Institute grant evaluating CGM versus blood glucose monitoring to guide insulin therapy in the primary care setting. 


Dr Bergenstal’s clinical efforts have been directed toward improving systems of care for patients with diabetes by translating new research findings into practice. He studies the effective utilisation of insulin therapy to optimise outcomes in both type 1 and type 2 diabetes. Dr Bergenstal has worked to standardise CGM metrics and the data display in the Ambulatory Glucose Profile Report, which is now being integrated directly into the electronic health record and organised to help guide and personalise diabetes management.


He teaches nationally and internationally on the importance of patient‐centred team care, has been listed in Best Doctors in America since it began in 1992, and has published more than 400 peer-reviewed scientific articles.